Cell Lysate Sample Handling with Simoa Bead-Based Assays

November 12, 2019

This document describes a novel Quanterix lysate diluent for running lysate samples with Simoa assays diluent.

Spotlight

BioCity

BioCity Nottingham is an address with international credibility and prestige. Established in 2003 BioCity was one of the first Bioscience incubators offering state-of-the-art laboratories and commercial office space to let/rent, alongside business support and services to early stage companies in the life sciences sector.

OTHER WHITEPAPERS
news image

Valorization of Starch to Biobased Materials

whitePaper | May 30, 2022

Many concerns are being expressed about the biodegradability, biocompatibility, and longterm viability of polymer-based substances. This prompted the quest for an alternative source of material that could be utilized for various purposes.

Read More
news image

Preparing Biologics for Commercialization

whitePaper | December 14, 2022

Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product.

Read More
news image

2022 Biosimilars Report: The U.S. Journey and Path Ahead

whitePaper | June 8, 2022

Cardinal Health is fortunate to sit at the crossroads of the United States (U.S.) healthcare system, engaging with stakeholders from across the industry including healthcare

Read More
news image

The EU Clinical Trials Regulation − What You Need to Know

whitePaper | March 22, 2022

The Clinical Trials Regulation has retained some definitions and refined others. For example the definition of “clinical study”: “Any investigation in relation to humans intended: (a) to discover or verify the clinical, pharmacological or other pharmacodynamic.

Read More
news image

New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

Read More
news image

Early engagement and regulatory considerationsfor biotech

whitePaper | May 10, 2022

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines

Read More

Spotlight

BioCity

BioCity Nottingham is an address with international credibility and prestige. Established in 2003 BioCity was one of the first Bioscience incubators offering state-of-the-art laboratories and commercial office space to let/rent, alongside business support and services to early stage companies in the life sciences sector.

Events